PL1841433T3 - Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego - Google Patents
Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowegoInfo
- Publication number
- PL1841433T3 PL1841433T3 PL06712847T PL06712847T PL1841433T3 PL 1841433 T3 PL1841433 T3 PL 1841433T3 PL 06712847 T PL06712847 T PL 06712847T PL 06712847 T PL06712847 T PL 06712847T PL 1841433 T3 PL1841433 T3 PL 1841433T3
- Authority
- PL
- Poland
- Prior art keywords
- composition
- nervous system
- central nervous
- system disorders
- treating central
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64700805P | 2005-01-27 | 2005-01-27 | |
EP06712847A EP1841433B1 (en) | 2005-01-27 | 2006-01-26 | Composition for treating central nervous system disorders |
PCT/JP2006/301704 WO2006080549A2 (en) | 2005-01-27 | 2006-01-26 | Method and composition for treating central nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1841433T3 true PL1841433T3 (pl) | 2012-07-31 |
Family
ID=36740907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06712847T PL1841433T3 (pl) | 2005-01-27 | 2006-01-26 | Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego |
Country Status (20)
Country | Link |
---|---|
US (2) | US8202909B2 (pl) |
EP (2) | EP2332545A1 (pl) |
JP (1) | JP5147404B2 (pl) |
KR (1) | KR101354771B1 (pl) |
CN (1) | CN101146541B (pl) |
AR (1) | AR055846A1 (pl) |
AU (1) | AU2006209072B2 (pl) |
BR (1) | BRPI0607084A2 (pl) |
CA (1) | CA2595898C (pl) |
DK (1) | DK1841433T3 (pl) |
ES (1) | ES2375082T3 (pl) |
HK (1) | HK1118716A1 (pl) |
IL (1) | IL184578A (pl) |
NO (1) | NO340257B1 (pl) |
NZ (1) | NZ556710A (pl) |
PL (1) | PL1841433T3 (pl) |
PT (1) | PT1841433E (pl) |
RU (1) | RU2440338C2 (pl) |
TW (1) | TWI384988B (pl) |
WO (1) | WO2006080549A2 (pl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
WO2008108322A2 (en) * | 2007-02-27 | 2008-09-12 | Sucampo Ag | Composition and method for protecting mitochondria |
KR101485212B1 (ko) * | 2007-07-19 | 2015-01-22 | 가부시키가이샤 아루떼꾸 우에노 | 11-데옥시-프로스타글란딘 화합물을 포함하는 약학 조성물 및 상기 화합물을 안정화시키는 방법 |
US8871752B2 (en) | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
US9084815B2 (en) | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
BR112013009163A2 (pt) * | 2010-10-15 | 2016-07-26 | Scinopharm Kunshan Biochemical Technology Co Ltd | processo para preparação de lubiprostona |
US9259409B2 (en) | 2011-01-24 | 2016-02-16 | Inceptum Research & Therapeutics, Inc. | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
RU2013151166A (ru) * | 2011-04-19 | 2015-05-27 | Сукампо Аг | Способ модуляции активности цитокинов |
NZ620300A (en) * | 2011-08-05 | 2015-09-25 | Sucampo Ag | Method for treating schizophrenia |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
AU2015334964B2 (en) * | 2014-10-21 | 2019-06-20 | Universitat De Les Illes Balears | Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1120243A (en) | 1970-03-09 | 1968-07-17 | Samuelsson Bengt | Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof |
BE786215A (fr) | 1971-07-14 | 1973-01-15 | American Cyanamid Co | Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation |
ZA764727B (en) * | 1975-09-02 | 1977-07-27 | Upjohn Co | Prostanoic acid derivatives |
SU845774A3 (ru) | 1976-04-20 | 1981-07-07 | Фармиталия Карло Эрба С.П.А. (Фирма) | Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ |
US4131738A (en) * | 1977-07-05 | 1978-12-26 | The Upjohn Company | 6-Hydroxy-PGE1 compounds |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
EP0444844B1 (en) | 1990-02-26 | 1995-01-18 | R-Tech Ueno Ltd. | New 15-dehydroxy-16-oxoprostaglandins |
TW224942B (pl) | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
JPH04187637A (ja) * | 1990-11-21 | 1992-07-06 | Ueno Seiyaku Oyo Kenkyusho:Kk | 記憶改善剤 |
JPH07113012B2 (ja) | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | 新規15−ケト−プロスタグランジン類 |
JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
US6242485B1 (en) | 1996-06-10 | 2001-06-05 | R-Tech Ueno | Endothelin antagonist |
ES2310013T3 (es) | 1997-11-28 | 2008-12-16 | Sucampo Ag | Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina. |
JP3703004B2 (ja) | 1998-07-15 | 2005-10-05 | 小野薬品工業株式会社 | 5−チア−ω−置換フェニル−プロスタグランジンE誘導体 |
AU3713600A (en) * | 1999-03-01 | 2000-09-21 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and metods of use |
TWI225398B (en) | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
WO2001070233A2 (en) * | 2000-03-24 | 2001-09-27 | Sucampo Ag | Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
US20040224995A1 (en) | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
CN1214794C (zh) * | 2003-09-08 | 2005-08-17 | 秦正红 | 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途 |
-
2006
- 2006-01-26 DK DK06712847.0T patent/DK1841433T3/da active
- 2006-01-26 AU AU2006209072A patent/AU2006209072B2/en not_active Ceased
- 2006-01-26 US US11/339,495 patent/US8202909B2/en not_active Expired - Fee Related
- 2006-01-26 CA CA2595898A patent/CA2595898C/en not_active Expired - Fee Related
- 2006-01-26 PL PL06712847T patent/PL1841433T3/pl unknown
- 2006-01-26 TW TW095103028A patent/TWI384988B/zh not_active IP Right Cessation
- 2006-01-26 JP JP2007535160A patent/JP5147404B2/ja not_active Expired - Fee Related
- 2006-01-26 RU RU2007132081/04A patent/RU2440338C2/ru active
- 2006-01-26 PT PT06712847T patent/PT1841433E/pt unknown
- 2006-01-26 CN CN2006800094248A patent/CN101146541B/zh not_active Expired - Fee Related
- 2006-01-26 BR BRPI0607084-1A patent/BRPI0607084A2/pt not_active Application Discontinuation
- 2006-01-26 WO PCT/JP2006/301704 patent/WO2006080549A2/en active Application Filing
- 2006-01-26 EP EP11155203A patent/EP2332545A1/en not_active Withdrawn
- 2006-01-26 KR KR1020077019366A patent/KR101354771B1/ko active IP Right Grant
- 2006-01-26 NZ NZ556710A patent/NZ556710A/en not_active IP Right Cessation
- 2006-01-26 ES ES06712847T patent/ES2375082T3/es active Active
- 2006-01-26 AR ARP060100290A patent/AR055846A1/es not_active Application Discontinuation
- 2006-01-26 EP EP06712847A patent/EP1841433B1/en active Active
-
2007
- 2007-07-12 IL IL184578A patent/IL184578A/en active IP Right Grant
- 2007-08-24 NO NO20074332A patent/NO340257B1/no not_active IP Right Cessation
-
2008
- 2008-09-18 HK HK08110344.4A patent/HK1118716A1/xx not_active IP Right Cessation
-
2012
- 2012-05-14 US US13/470,377 patent/US20120225938A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2595898A1 (en) | 2006-08-03 |
RU2007132081A (ru) | 2009-03-10 |
RU2440338C2 (ru) | 2012-01-20 |
HK1118716A1 (en) | 2009-02-20 |
US20060194880A1 (en) | 2006-08-31 |
ES2375082T3 (es) | 2012-02-24 |
AU2006209072B2 (en) | 2011-02-24 |
NO20074332L (no) | 2007-10-17 |
KR101354771B1 (ko) | 2014-01-22 |
EP2332545A1 (en) | 2011-06-15 |
IL184578A0 (en) | 2007-10-31 |
CA2595898C (en) | 2015-04-28 |
CN101146541A (zh) | 2008-03-19 |
EP1841433A2 (en) | 2007-10-10 |
TW200642690A (en) | 2006-12-16 |
WO2006080549A3 (en) | 2007-07-05 |
US8202909B2 (en) | 2012-06-19 |
JP5147404B2 (ja) | 2013-02-20 |
JP2008528440A (ja) | 2008-07-31 |
IL184578A (en) | 2015-02-26 |
PT1841433E (pt) | 2012-02-01 |
NO340257B1 (no) | 2017-03-27 |
AR055846A1 (es) | 2007-09-12 |
DK1841433T3 (da) | 2012-01-16 |
BRPI0607084A2 (pt) | 2009-08-04 |
EP1841433B1 (en) | 2011-11-30 |
CN101146541B (zh) | 2012-04-11 |
AU2006209072A1 (en) | 2006-08-03 |
TWI384988B (zh) | 2013-02-11 |
KR20070107065A (ko) | 2007-11-06 |
NZ556710A (en) | 2010-08-27 |
WO2006080549A2 (en) | 2006-08-03 |
US20120225938A1 (en) | 2012-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1841433T3 (pl) | Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego | |
EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
IL186450A0 (en) | Methods for treating anxiety related disorders | |
IL187168A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
IL180187A (en) | Composition for treating inflammatory disorders | |
HK1157575A1 (en) | Treating neurological disorders | |
HK1115341A1 (en) | Composition for treating mental health disorders | |
IL185016A0 (en) | Compounds for the treatment of proliferative disorders | |
IL178648A0 (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
IL190913B (en) | Preparations for the treatment of sweating disorders | |
EP2170309A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
ZA200809528B (en) | Treatment for depressive disorders | |
HK1101140A1 (en) | Compositions and methods for treating neurological disorders | |
IL176836A0 (en) | Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders | |
ZA200809527B (en) | Treatment for depressive disorders | |
PL1993589T3 (pl) | Sposoby leczenia chorób neurologicznych | |
ZA200809284B (en) | Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders | |
ZA200804951B (en) | Compositions and methods for treating CNS disorders | |
IL198856A0 (en) | Compounds useful for treating neurodegenerative disorders | |
IL187439A0 (en) | Compounds useful for treating neurodegenerative disorders | |
IL162288A0 (en) | Compositions and methods for treating neurodegenerative disorders | |
HK1118286A1 (en) | Dipyrazoles as central nervous system agents | |
ZA200708543B (en) | Methods for treating anxiety related disorders | |
EP1890711A4 (en) | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES | |
EP1942909A4 (en) | METHODS OF TREATING RESPIRATORY DISORDERS |